Kagocel has again become the laureate of the "Russian Pharma Awards"

1 Dec 2016 hosted the jubilee ceremony of awarding prize of the "Russian Pharma Awards". The results of the vote practitioners of Russian antiviral drug Kagocel recognized as the best in the nomination "the drug in the prevention and treatment of ARVI and flu".

As the organizer of the award were the largest Russian-language social network for doctors "Doctor at work". More than 500,000 doctors determined the best representatives of the pharmaceutical industry to cast a vote for most effective, in their opinion, drugs.

Antiviral drug Kagocel for the third year in a row becomes the winner of the award "Russian Pharma Awards", which once again confirms the high level of trust of doctors to Kagocel.

Experts say the effectiveness of the drug, the possibility of the appointment until the 4th day from the onset of the disease, a high level of security and a wide evidence base. At the same time manufacturer of Kagocel nearmedic has recently completed a unique post-licensure study "Treatment of SARS and influenza in routine clinical practice (FLU-EE)". The project involved 262 medical center from Russia, Moldova, Armenia and Georgia and more than 18 000 patients aged 18 to 93 years with an established diagnosis of SARS and influenza. Kagocel in the complex therapy has demonstrated efficacy in patients of different age and severity of the disease, regardless of appointment time, including delayed treatment. The study showed that the use of the drug leads to a reduction in the number of patients with complications receiving systemic antibacterial drugs by 51%.

Reference

"Russian Pharma Awards" - an annual award in the field of pharmaceuticals and medicine, which has proved itself as objective and independent. Users of the social network "Doctor at work" anonymously vote for the best, in their opinion, drugs are in different categories, giving preference to those with proven effectiveness of their own experience.

Kagocel is an original antiviral drug developed by Russian scientists for the treatment and prevention of influenza and ARVI for children and adults from the age of three. The drug is available without a doctor's prescription, it has a high safety profile and convenient dosage regimen.